2026: The year of consolidation of medical cannabis in Brazil

The year 2026 arrives with solid prospects for the medical cannabis sector in Brazil. After a period marked by regulatory advances, expanded access, and growing interest from the medical community, we are entering a decisive phase: consolidation. I work daily on the front lines of this segment and closely observe what patients, doctors, and the industry expect from the future. And I have no doubt: we are about to witness one of the biggest structural leaps in this emerging market.

One of the key points for 2026 was the expectation of significant updates to RDC 327/2019, the regulation that governs the national medical cannabis market, which happened with the approval of the new RDC 1.015.  Regulation has advanced significantly in recent years, but there are still necessary adjustments to ensure more legal certainty, predictability for companies, and, most importantly, broader and less bureaucratic access for patients. The consolidation of this regulation has the potential to unlock bottlenecks, attract new investments, and allow healthcare professionals to operate with more clarity and technical support. We also expect the formation of more specialized doctors, with greater ability and comfort to prescribe, monitor, and guide treatments with cannabinoids.

Another trend that is expected to intensify in 2026 is the advancement of the pharmaceutical industry in the field of medical cannabis. We are already seeing indications of national and international laboratories working on new, more modern, stable, and condition-specific formulations. With the growth of research — both in Brazil and abroad — we will have access to more innovative medications, capable of serving varied patient profiles. This scenario points to something even more transformative: the popularization and diversity of products should naturally result in price reductions. More options generate competitiveness, innovation, and democratization of access, a fundamental step for CBD to move from a restricted alternative to a resource accessible to the Brazilian population.

The market, in fact, indicates a billion-dollar growth. National projections estimate that the medical cannabis sector could reach between R$ 2 and R$ 6 billion in the coming years, a clear sign of maturity and expansion. This advancement will inevitably be accompanied by the opening of new specialized pharmacies, the strengthening of companies that work with regulatory rigor, and the expansion of the patient base in treatment. The population is indeed more informed — but there is still a long way to go in combating stigma. It is precisely here that the responsibility of companies in the sector becomes even greater: to educate, guide, and demystify.

In 2026, the focus of the business sector should follow this growth movement responsibly. We plan to expand to other cities and states, bringing the personalized, dedicated, and technical care that we currently offer in Curitiba (PR). We want to be increasingly close to patients, working side by side with the industry to ensure that the most modern, certified, and safe products are available to those in need. We will do this with the same philosophy that has brought us this far: combining support, knowledge, and scientific rigor.

Finally, 2026 should be the year when Brazil takes decisive steps towards the maturity of the medical cannabis market. With regulatory adjustments, price reductions, research advancements, increased medical adherence, and popularization of the topic, we will build a fairer, more accessible, and more aligned scenario with the real needs of patients. If today we talk about potential, tomorrow we will talk about reality. And we, as pioneering companies, have the responsibility and privilege to help build this future.